Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Menopausal Hot Flashes Market To Reach US$5.28 Bn By 2023, Estrogen Leads Hormonal Products In Revenue And Prescription Volume

|Includes: Meridian Resource Corp. (TMR)

Transparency Market Research has published a new market report titled, "Menopausal Hot Flashes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023." According to the report, the global menopausal hot flashes market was valued at US$3.77 bn in 2014 and is projected to expand at a CAGR of 3.7% from 2015 to 2023 to reach US$5.28 bn by 2023.

Hot flashes are the most common vasomotor symptom of menopause complications. The usual symptoms include sudden sensation of intense warmth spreading over body lasting for several minutes leading to sweating, red flush, and palpitations. Hot flashes may occur during the day or at night (also known as night sweats). The intensity of hot flashes vary from woman to woman depending on several physiochemical factors. It may be mild, moderate and troublesome, or severe and debilitating. Hormone replacement therapy (HRT) has been considered as gold standard for the treatment of menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems. Other therapies include intake of vitamin E supplements and anti-depressants along with various complementary therapies. In the U.S. and other developed countries approximately 70% of menopausal women suffer from hot flashes that can last for several years. According to a publication by Harvard Medical School, on average, hot flashes can last for about 7 years to 11 years.

The report explores the vast scope of menopausal hot flashes market and draws upon the market analysis through two broad perspectives: product, and geography. On the basis of product types, the market has been categorized into hormonal and non-hormonal products. Estrogen and progesterone are the two hormones used to reduce hot flashes. Furthermore, these hormones are also prescribed in combination in certain women with high risk cancer. Estrogen accounted for the largest share of the global menopausal hot flashes market in terms of revenue as well as prescription volume. Estrogen's position in hot flashes treatment market is unchallenged as none of the other available drug is as effective as estrogen. Some of the recent studies show that non-estrogen drugs may have up to 70% of the effectiveness of estrogen therapy when treating hot flashes. Premarin was the largest selling estrogen product in 2014. The drug has recorded over billion sale in 2014. Combination drugs primarily include treatment with estrogen and progesterone prescribed to women with intact uterus and have moderate to severe symptoms of menopause. Amongst the combination product, Prempro, Duavee, and Activella were the major market share holders in 2014.

The aftermaths of the Women's Health Initiative study of HRT in menopausal women have encouraged many physicians to restrict the use of HRT to relieve hot flashes. Now a days, non-hormonal therapy is being considered as a treatment to avoid the increased risk of cancer in certain high risk populations. Non-hormonal therapy includes antidepressants and other prescription drugs that offer relief for some women. Brisdelle is the only antidepressant medication approved by the FDA for treating hot flashes.

Get a Sample of this Report:

On the basis of geography, the menopausal hot flashes market has segmented into: North America, Europe, Asia Pacific, Latin America, Middle East and North Africa (MENA), and Rest of the World (RoW). North America was the largest regional market for menopausal hot flashes treatment, followed by Europe in 2014. Asia Pacific is anticipated to witness the fastest growth rate during the forecast period. In addition to large population pool, rising disposable income, rapid urbanization, and increase in women's health expenditure across the region also support the market growth in the region. The menopausal hot flashes market in Rest of the World offers large opportunities and is projected to expand at a decent rate in the next few years. Growth of the market is due to improving health care infrastructure and growing menopause women in this region.

The menopausal hot flashes market is highly fragmented due to the presence of large number of small and medium generic manufacturing companies across the world. Top ten manufacturers accounted for around 44.5% of the market in 2014. Key players operating in the market include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk Corporation, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

The global menopausal hot flashes market has been segmented as follows:

Global Menopausal Hot Flashes Market, by Product

  • Hormonal Products

    • Estrogen

      • Premarin

      • Vivelle, Vivelle-Dot

    • Progesterone

      • Prometrium

    • Combination Product

      • Prempro

      • Duavee

    • Non-Hormonal Product

      • Brisdelle

Global Menopausal Hot Flashes Market, Pipeline Analysis

  • Phase I and II Drugs

  • Phase III Drugs

Global Menopausal Hot Flashes Market, by Geography

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Rest of Europe

  • Asia Pacific

    • Australia

    • Japan

    • India

    • China

    • Rest of Asia Pacific

  • Rest of the World

    • Latin America

    • MENA

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,


NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453